Trevena Drug Patent Portfolio

Trevena owns 1 orange book drug protected by 5 US patents Given below is the list of Trevena's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11077098 Opioid receptor ligands and methods of using and making same 23 Mar, 2032
Active
US11931350 Opioid receptor ligands and methods of using and making same 23 Mar, 2032
Active
US8835488 Opioid receptor ligands and methods of using and making same 23 Mar, 2032
Active
US9309234 Opioid receptor ligands and methods of using and making same 23 Mar, 2032
Active
US9642842 Opioid receptor ligands and methods of using and making same 23 Mar, 2032
Active


Given below is the list of recent legal activities going on the following drug patents of Trevena.

Activity Date Patent Number
Patent litigations
Patent eGrant Notification 19 Mar, 2024 US11931350
Email Notification 19 Mar, 2024 US11931350
Recordation of Patent eGrant 19 Mar, 2024 US11931350
Recordation of Patent Grant Mailed 19 Mar, 2024 US11931350
Mail Patent eGrant Notification 19 Mar, 2024 US11931350
Patent Issue Date Used in PTA Calculation 19 Mar, 2024 US11931350
Email Notification 29 Feb, 2024 US11931350
Issue Notification Mailed 28 Feb, 2024 US11931350
Filing Receipt - Corrected 06 Feb, 2024 US11931350
Email Notification 06 Feb, 2024 US11931350
Application Is Considered Ready for Issue 05 Feb, 2024 US11931350
Dispatch to FDC 05 Feb, 2024 US11931350
Issue Fee Payment Received 01 Feb, 2024 US11931350
Response to Reasons for Allowance 01 Feb, 2024 US11931350
Issue Fee Payment Verified 01 Feb, 2024 US11931350


Trevena Drug Patents' Oppositions Filed in EPO

Trevena drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 28, 2018, by Generics (Uk) Ltd. This opposition was filed on patent number EP12760456A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP12760456A Feb, 2018 Generics (UK) Ltd Opposition rejected


Trevena's Family Patents

Trevena drugs have patent protection in a total of 23 countries. It's US patent count contributes only to 21.2% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Trevena Drug List

Given below is the complete list of Trevena's drugs and the patents protecting them.


1. Olinvyk

Olinvyk is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11077098 Opioid receptor ligands and methods of using and making same 23 Mar, 2032
(7 years from now)
Active
US11931350 Opioid receptor ligands and methods of using and making same 23 Mar, 2032
(7 years from now)
Active
US8835488 Opioid receptor ligands and methods of using and making same 23 Mar, 2032
(7 years from now)
Active
US9309234 Opioid receptor ligands and methods of using and making same 23 Mar, 2032
(7 years from now)
Active
US9642842 Opioid receptor ligands and methods of using and making same 23 Mar, 2032
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Olinvyk's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List